References
- Attaran D, Lari SM, Towhidi M, et al. (2010). Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chronic Obstr Pulmonary Dis, 5, 335–40
- Fedeles BI, Zhu AY, Young KS, et al. (2011). Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target. J Biol Chem, 286, 33910–20
- Ghabili K, Agutter PS, Ghanei M, et al. (2011). Sulfur mustard toxicity: history, chemistry, pharmacokinetics, and pharmacodynamics. Crit Rev Toxicol, 41, 384–403
- Ghanei M, Adibi I, Farhat F, Aslani J. (2008). Late respiratory effects of sulfur mustard: how is the early symptoms severity involved? Chron Respir Dis, 5, 95–100.
- Ghanei M, Harandi AA. (2007). Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol, 19, 451–6
- Ghanei M, Harandi AA. (2010). Lung carcinogenicity of sulfur mustard. Clin Lung Cancer, 11, 13–7
- Ghanei M, Harandi AA. (2011). Molecular and cellular mechanism of lung injuries due to exposure to sulfur mustard: a review. Inhal Toxicol, 23, 363–71
- Ghanei M, Sheyacy M, Abbasi MA, et al. (2011). Correlation between the degree of air trapping in chest HRCT and cardiopulmonary exercise test parameters: could HRCT be a predictor of disease severity? Arch Iran Med, 14, 86–90.
- Martens ME, Smith WJ. (2008). The role of NAD+ depletion in the mechanism of sulfur mustard-induced metabolic injury. Cutan Ocul Toxicol, 27, 41–53
- Pourfarzam S, Ghazanfari T, Yaraee R, et al. (2009). Serum levels of IL-8 and IL-6 in the long term pulmonary complications induced by sulfur mustard: Sardasht-Iran Cohort Study. Int Immunopharmacol, 9, 1482–8
- Rezaian GR, Emad A, Ghayumi MA, et al. (2008). Exercise intolerance and chronotropic impairment-The long-term cardiovascular sequelae of mustard gas exposure: a paired-comparative study. Environ Toxicol Pharmacol, 26, 212–5
- Tang FR, Loke WK. (2012). Sulfur mustard and respiratory diseases. Crit Rev Toxicol, 42, 688–702